Maxim initiated coverage of Lexaria Bioscience with a Buy rating and $2 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LEXX:
- Lexaria Bioscience granted patent for DehydraTECH-Nicotine
- Lexaria Bioscience announces publication on DehydraTECH-CBD research
- Lexaria Bioscience provides update on DEM-A22-1, EPIL-A21-1 programs
- Lexaria Bioscience reports additional findings from DIAB-A22-1 study
- Lexaria Bioscience appoints Mike Shankman as outsourced CFO